< Back to previous page
Researcher
Geert Bultynck
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Molecular and Cellular Signaling (Division)
Responsible
From1 Oct 2021 → Today - Laboratory of Molecular and Cellular Signaling (Division)
Member
From1 Oct 2007 → Today
Projects
1 - 10 of 49
- Implementing assays to evaluate the impact of novel BAPTA variants on cellular Ca2+ signaling nanodomainsFrom1 Apr 2024 → TodayFunding: BOF - mobility
- Exploiting structural insights in IP3 receptor function to develop novel, allosteric inhibitors of IP3 receptor channels (SINFONIC)From1 Oct 2023 → TodayFunding: BOF - projects
- 'Mito-tracking’ the phenotyping transition of pancreatic stellate cellsFrom1 Oct 2023 → TodayFunding: BOF - projects
- Advancing the understanding of the IP3R/Bcl-xL complex: from novel molecular insights towards relevance for precision therapeutics in cancer cell deathFrom3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The development of a novel intracellular Ca2+-buffering agent and its impact on cell functionFrom2 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- When size matters: a platform to study molecular interactions and multimerisationFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Next-generation, multi-technology immune-monitoring and easy-access spectral flow cytometryFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Scientific research community CaSign.From1 Jan 2022 → TodayFunding: FWO scientific research network
- Bcl-2/IP3R channel structural dynamics underlying complex formation, function and disease (BInamics)From1 Jan 2022 → TodayFunding: FWO research project (including WEAVE projects)
- Phosphorylation status of GRP75 and its impact on MAMs dynamics and functionFrom1 Jan 2021 → 31 Oct 2021Funding: BOF - postdoctoral mandates
Publications
1 - 10 of 260
- Recent advances in canonical versus non-canonical Ca2+-signaling-related anti-apoptotic Bcl-2 functions and prospects for cancer treatment.(2024)
Authors: Geert Bultynck
Pages: 119713 - IP3RPEP6, a novel peptide inhibitor of IP3 receptor channels that does not affect connexin-43 hemichannels(2024)
Authors: Geert Bultynck
- Cellular effects of BAPTA: Are they only about Ca2+chelation?(2024)
Authors: Flore Sneyers, Steven Verhelst, Geert Bultynck
- The Complex Effects of PKM2 and PKM2:IP3R Disruption on Intracellular Ca2+ Handling and Cellular Functions(2023)
Authors: Geert Bultynck, Jan Parys
- Modalities of cell death, survival and adaptation: The role of the Ca2+-signaling toolkit(2023)
Authors: Jan Parys, Geert Bultynck
- BAPTA, the intracellular calcium chelator: how does it kill cancer cells?(2023)
Authors: Flore Sneyers, Geert Bultynck
Number of pages: 123 - Intracellular BAPTA directly inhibits PFKFB3, thereby impeding mTORC1-driven Mcl-1 translation and killing MCL-1-addicted cancer cells(2023)
Authors: Flore Sneyers, Martijn Kerkhofs, Rita La Rovere, Mieke Dewerchin, Bart Ghesquière, Geert Bultynck
- Human IP3 receptor triple knockout stem cells remain pluripotent despite altered mitochondrial metabolism(2023)
Authors: Ludo Van Den Bosch, Geert Bultynck
- LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent manner(2023)
Authors: Rita La Rovere, Evy Lobbestael, Veerle Baekelandt, Geert Bultynck, Jan Parys
- Introducing the Special Issue on "Emerging Concepts & Non-Canonical Pathways in Cellular Signaling"(2023)
Authors: Geert Bultynck
Patents
1 - 2 of 2
- Use of compounds that selectively modulate astrocytic release of substances through hemichannels of connexins and pannexins, without influencing gap junctions, for the treatment of psychiatric disorders (Inventor)
- COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS (Inventor)